Kuria Therapeutics, a Little Rock, Ark.-based pharmaceutical company developing novel ophthalmic and dermal therapeutics, closed its first fundraising round.
The amount of the deal was not disclosed.
The company intends intends to use the funds to advance R&D activities to support ongoing preclinical development activities ahead of a planned Series A raise. This round will support selection of a lead ophthalmic formulation, preclinical proof-of-concept studies, and initiation of key manufacturing activities for IND-enabling work and future clinical studies.
Led by Dr. Keith Ward, President and Chief Executive Officer, Kuria Therapeutics is a pharmaceutical company dedicated to the development of novel therapeutics for ophthalmic and dermal disease. Its lead product candidate is a topical ophthalmic formulation of SCO-116, a novel Nrf2 activator being developed under a license from Scohia Pharma. The topical ophthalmic product (KTX-1161) is focused on the corneal endothelium, a single layer of cells responsible for corneal transparency and vision.
FinSMEs
09/09/2022